Chemours Company Common S (CC) 8.18 $CC Why Did

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Chemours Company [The] Common S (CC) 8.18 $CC

Why Did Chemours Co. Stock (CC) Close 17% Up on the Day?
Andrew Steele - Zacks Investment Research - Fri Jul 08, 4:35PM CDT
Both Chemours Co. and DuPont were caught up in a messy legal case regarding dumping chemicals into waterways. So what could have happened to have Chemours' stock rise?
CC: 8.18 (+0.25), DD: 65.94 (+1.70)

Chemours Announces Dates for Second Quarter Earnings Release and Webcast Conference Call
PR Newswire - Tue Jul 05, 3:52PM CDT
The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, announced it will release second quarter financial results after market close on August 8, 2016. The company will conduct its second quarter 2016 webcast conference call on Tuesday, August 9, 2016 at 8:30 a.m. Eastern Time. The call is open to the public and can be accessed via live webcast and teleconference.
CC: 8.18 (+0.25)

Why Investors Love These Basic Materials' Stocks? - Chemours, Pan American Silver, Axiall, and Celanese
PR Newswire - Tue Jun 21, 6:45AM CDT
The Basic Materials sector is constantly shifting given its sensitivity toward inconsistencies in supply and demand. At the close of yesterday's trading session, four stocks have impressed, and Stock-Callers.com has released their trade alerts for today: The Chemours Co. (NYSE: CC), Pan American Silver Corp. (NASDAQ: PAAS), Axiall Corp. (NYSE: AXLL), and Celanese Corp. (NYSE: CE). Learn more about these stocks and access their free alerts by clicking below:
CE: 68.57 (+1.57), AXLL: 32.42 (-0.03), CC: 8.18 (+0.25), PAAS: 18.14 (-0.47)

Chemours Inks $325M Deal to Sell Sulfur Products to Veolia
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 4:28PM CDT
The Chemours Company (CC) has cut a definitive deal to divest its Sulfur Products business, which is part of its Chemical Solutions segment, to Veolia North America for $325 million in cash.
ALB: 85.23 (+1.60), CC: 8.18 (+0.25), DD: 65.94 (+1.70), DOW: 50.95 (+1.10)

Chemours Signs Definitive Agreement to Sell Sulfur Products to Veolia
PR Newswire - Tue Jun 14, 4:06AM CDT
The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, has signed a definitive agreement to sell the assets which comprise its Sulfur Products business, part of its Chemical Solutions segment, to Veolia North America for $325 million in cash. The company anticipates closing the transaction within the second half of 2016, subject to customary closing conditions and regulatory approvals.
CC: 8.18 (+0.25)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against The Chemours Company and Advises Investors with Losses to Contact the Firm
BusinessWire - Fri Jun 03, 8:20PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by The Chemours Company ("Chemours" or the "Company" (NYSE: CC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
CC: 8.18 (+0.25)

Glancy Prongay & Murray Commences Investigation on Behalf of The Chemours Company Investors
BusinessWire - Fri Jun 03, 11:48AM CDT
Glancy Prongay & Murray LLP ("GPM" announces an investigation on behalf of investors of The Chemours Company ("Chemours" or the "Company" (NYSE: CC) concerning the Company and its officers' possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
CC: 8.18 (+0.25)

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against The Chemours Company and Advises Investors to Contact the Firm
BusinessWire - Thu Jun 02, 5:31PM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by The Chemours Company ("Chemours" or the "Company" (NYSE: CC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
CC: 8.18 (+0.25)

Chemours Strongly Refutes Citron Report
PR Newswire - Thu Jun 02, 4:05PM CDT
The Chemours Company (Chemours) (NYSE: CC) strongly refutes the report by Citron Research issued today.
CC: 8.18 (+0.25)

INVESTOR ALERT: Investigation of The Chemours Company Announced by Law Offices of Howard G. Smith
BusinessWire - Thu Jun 02, 2:30PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of The Chemours Company ("Chemours" or the "Company" (NYSE: CC) concerning the Company and its officers' possible violations of federal securities laws.
CC: 8.18 (+0.25)

Chemours Begins Commercial Operations of New Altamira TiO2 Line in Mexico
PR Newswire - Tue May 17, 6:30AM CDT
The Chemours Company ("Chemours" (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, announced that it has begun the commercial startup of its new titanium dioxide (TiO2) line at its Altamira plant in the Mexican state of Tamaulipas.
CC: 8.18 (+0.25)

The Chemours Company Extends Exchange Offer for Its 6.625% Senior Notes Due 2023 and 7.000% Senior Notes Due 2025
PR Newswire - Mon May 16, 12:00PM CDT
The Chemours Company ("Chemours" (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, announced today that it has extended its previously announced offer (the "Exchange Offer" to exchange any and all of its $1,350 million aggregate principal amount of 6.625% Senior Notes due 2023 (the "2023 Notes" , $750 million aggregate principal amount of 7.000% Senior Notes due 2025 (the "2025 Notes" and EUR 360 million aggregate principal amount of 6.125% Senior Notes due 2023 which were issued in a private placement on May 12, 2015 (the "Euro Notes," and together with the 2023 Notes and the 2025 Notes, the "Original Notes" for an equal principal amount of its $1,350 million aggregate principal amount of 6.625% Senior Notes due 2023, $750 million aggregate principal amount of 7.000% Senior Notes due 2025 and EUR 360 million aggregate principal amount of 6.125% Senior Notes due 2023, which have been registered under the Securities Act of 1933, as amended.
CC: 8.18 (+0.25)

Moving Average Crossover Alert: Chemours (CC)
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:13AM CDT
The Chemours Company (CC) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
CC: 8.18 (+0.25)

Why Chemours Company (CC) Could Be a Top Value Stock Pick
Zacks Equity Research - Zacks Investment Research - Fri May 06, 7:30AM CDT
Chemours Company may be a strong candidate for value investing, since it has a low PE, solid outlook and a decent dividend.
CC: 8.18 (+0.25)

Chemours to Invest in Expanded Capacity for High Growth Opteon(TM) Products
PR Newswire - Mon May 02, 3:15PM CDT
The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, takes another step in its five-point transformation plan by investing in large-scale manufacturing to expand supply of its Opteon(TM) family of products.
CC: 8.18 (+0.25)

Chemours Fluoroproducts President Retires; Replacement Named
PR Newswire - Fri Apr 29, 7:30AM CDT
The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, announced today that Thierry Vanlancker, president of its fluoroproducts business, is retiring. Paul Kirsch, senior vice president, supply chain and operations at Henkel AG & Company, will take over Vanlancker's role, relocating to Chemours global headquarters in Wilmington, Delaware. Vanlancker and Kirsch will work closely together to ensure a smooth transition for customers and other company stakeholders.
CC: 8.18 (+0.25)

Chemours Announces Second Quarter Dividend
PR Newswire - Wed Apr 27, 3:30PM CDT
The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, announced today that the Board of Directors of Chemours declared a quarterly cash dividend of $0.03 per share on the company's common stock for the second quarter of 2016. The dividend will be paid on June 15, 2016 to stockholders of record as of the close of business on May 17, 2016.
CC: 8.18 (+0.25)

Chemours Signs Definitive Agreement to Sell Clean and Disinfect Business to LANXESS
PR Newswire Europe - Mon Apr 25, 6:30AM CDT
Agreement Moves Chemours Closer to Completing Strategic Review of Chemical Solutions
CC: 8.18 (+0.25)

Why Metals Stocks Surged on Tuesday
Travis Hoium, The Motley Fool - Motley Fool - Tue Apr 19, 3:04PM CDT
Image source: Pixabay. What: Shares of materials and metals stocks surged on Tuesday as global prices rose to a new high. Century Aluminum Co. , Chemours Co. , Joy Global , Companhia Siderurgica Nacional , and Vale SA each went up over...
SID: 2.90 (+0.12), JOY: 23.88 (+1.40), CENX: 8.00 (+0.74), VALE: 5.35 (+0.23), CC: 8.18 (+0.25)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 9

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 12

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 12

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 11

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 8

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 16

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 11

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 12

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 14

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Women Through the Gettysburg Salon Experience

Updated Category News Views 116

Reimagining Women's Spaces Through the Gettysburg Salon The Gettysburg Salon is a vibrant platform where women can express themselves creatively and engage in thought-provoking dialogues. This initiative began with three passionate individuals who envisioned a safe space for women to explore their identities, aspirations, and challenges through art and conversation. In a...

Continue Reading
Transforming Off-Road Adventures: Upfit UTV and OMI Innovation

Updated Category News Views 165

Transforming Off-Road Adventures: Upfit UTV and OMI Innovation Upfit UTV, a subsidiary of Fox Factory known for customizing high-performance vehicles, has joined forces with OMI, a leader in electric powertrain engineering. Together, they are redefining off-road adventures with their groundbreaking Fusion-Drive technology. This innovation not only elevates performance but...

Continue Reading
Investor Alert: AstraZeneca Faces Class Action Lawsuit Under SEC Laws

Updated Category News Views 278

Investor Alert Regarding AstraZeneca Securities Class Action Kahn Swick & Foti, LLC, founded by former Attorney General Charles C. Foti, Jr., is highlighting crucial information for investors in AstraZeneca PLC (NASDAQ: AZN) who may have incurred losses exceeding $100,000. The firm reminds those affected that they need to file lead plaintiff applications for their class...

Continue Reading
Important Class Action for GSK plc Investors: Know Your Rights

Updated Category News Views 208

GSK Faces Class Action Lawsuit: Key Information for Investors Levi & Korsinsky, LLP has announced a class action securities lawsuit involving GSK plc, a well-known pharmaceutical company traded on the NYSE under the ticker GSK. This lawsuit is particularly significant for investors who have been adversely affected during a specified period concerning the securities of...

Continue Reading
Denny’s Fundraiser for No Kid Hungry: Making a Difference

Updated Category News Views 435

Denny’s Annual Fundraiser for No Kid Hungry Returns Denny’s is excited to bring back its annual in-restaurant fundraiser to support No Kid Hungry, a national initiative focused on ending childhood hunger in the United States. This campaign will run for a designated period, allowing Denny's restaurants to make a meaningful difference by ensuring that children have...

Continue Reading